eras-601
Small moleculeexperimental
Clinical trial activity
4 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Dec 15, 2020 (NCT04670679)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Protein-tyrosine phosphatase 2CALLOSTERIC ANTAGONIST
PTPN11 allosteric antagonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06957327 | Phase 1/Phase 2 (Phase 2) | Apr 25, 2025 | Memorial Sloan-Kettering Cancer Center |
| NCT05279859 | Phase 1/Phase 2 (Phase 2) | Mar 15, 2022 | Antengene Corporation, Erasca, Inc. |
| NCT04959981 | Phase 1/Phase 2 (Phase 2) | Sep 2, 2021 | Erasca, Inc., Vigeo Therapeutics, Inc. |
| NCT04670679 | Phase 1 | Dec 15, 2020 | Erasca, Inc. |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Erasca, Inc. | For profit | 3 | 3 | 2 | 2020 |
| Antengene Corporation | For profit | 1 | 0 | 1 | 2022 |
| Memorial Sloan-Kettering Cancer Center | Academic/Hospital | 1 | 1 | 1 | 2025 |
| Vigeo Therapeutics, Inc. | For profit | 1 | 0 | 1 | 2021 |
4 organizations
Page 1 / 1